# EDGAR Filing Document

**Accession Number:** 0001645666
**File Stem:** 0001140361-26-020547
**Filing Date:** 2026-5
**Character Count:** 7665
**Document Hash:** cfeaf69c0a4dd66f73258e66e6b0bb85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-020547.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001140361-26-020547

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kezar Life Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001645666
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473366145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-284712
- **FILM NUMBER:** 26963128

**BUSINESS ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-822-5600

**MAIL ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

#### As filed with the Securities and Exchange Commission on May 11, 2026

#### Registration No. 333-284712

#### <br>

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

------

#### Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-284712

#### FORM S-3

#### REGISTRATION STATEMENT

#### UNDER

#### THE SECURITIES ACT OF 1933

#### <br>

------

## KEZAR LIFE SCIENCES, INC.

#### (Exact Name of Registrant as Specified in Its Charter)

------

---

| | |
|:---|:---|
| **Delaware** | **47-3366145** |
| **(State or Other Jurisdiction of Incorporation or Organization)** | **(IRS Employer Identification No.)** |

---

#### 4000 Shoreline Court, Suite 300

#### South San Francisco, California 94080

#### (Address of Principal Executive Offices, including Zip Code)

#### Michael Hearne

#### Chief Financial Officer

#### Kezar Life Sciences, Inc.

#### 77 Upper Rock Circle, Suite 700

#### Rockville, Maryland 20850
(250) 744-2487

#### (Name, Address and Telephone Number, including Area Code, of Agent for Service)

#### Copies to :

#### Andrew Marmer

#### Jared Fertman

#### Willkie Farr & Gallagher LLP

#### 787 Seventh Avenue

#### New York, NY 10019-6099
(212) 728-8000

#### Bill Roegge

#### Rita Sobral

#### Cooley LLP

#### 55 Hudson Yards

#### New York, NY 10001-2157
(212) 479-6000

#### (Name, address, and telephone number, including area code, of agent for service)

**Approximate date of commencement of proposed sale to the public:** Not applicable.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 431(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

------

#### DEREGISTRATION OF SECURITIES

This Post-Effective Amendment (the "<u>Post-Effective Amendment</u>") filed by Kezar Life Sciences, Inc., a Delaware corporation (the "<u>Registrant</u>"), relates to the following Registration Statement on Form S-3 (the "<u>Registrations Statement</u>"):

1. Registration Statement No. <u>333-284712</u>, registering the sale of up to $400,000,000 of Common Stock offered by the Registrant, which was filed with the Securities and Exchange Commission on February 5, 2025 and declared effective on February 10, 2025.

On March 30, 2026, the Registrant entered into an Agreement and Plan of Merger (the "<u>Merger Agreement</u>") with Aurinia Pharma U.S., Inc., a Delaware corporation ("<u>Parent</u>"), and Aurinia Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("<u>Merger Sub</u>"). Pursuant to the Merger Agreement, on May 11, 2026, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the "<u>Merger</u>"). In the Merger, each share of common stock, par value $0.001 per share, of the Company (the "<u>Shares</u>") (other than (i) Shares owned or held in the Company's treasury immediately prior to the Effective Time, (ii) Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (iii) Shares held by any stockholder of the Registrant who properly exercised appraisal rights under Delaware law) was converted into the right to receive (i) $6.955 per Share in cash and (ii) one non-transferable contractual contingent value right for each Share.

As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance or resale that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statement that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statement.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments to the Registration Statements and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on May 11, 2026. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

---

| |
|:---|
| **KEZAR LIFE SCIENCES, INC.** |
|  By: /s/ Michael Hearne |
|  Name: Michael Hearne |
|  Title: Chief Financial Officer |

---

------